Daewoong expects sales of 4 new drugs to rise

Sales Synergy with Fexuclue, a new P-CAB drug

No. 1 antidepressant, With Lexapro, Herceptin Similar Ogivri,

Daewoong Pharmaceutical expects sales to rise through its new drug introduced along with the new drug Fexuclue, a new drug for gastroesophageal reflux disease.

 

This includes biosimilars such as Lexapro, Ogivri, and Alymsys, the No.

 

1 items in the antidepressant market.

 

According to industries on the 14th, Daewoong Pharmaceutical is planning to continue its performance increase through its new drug introduced this year.

 

Last year, Daewoong Pharmaceutical recorded its highest-ever performance with sales of 1.1530 trillion won and operating profit of 88.9 billion won.

 

The driving force behind the rise in sales is P-CAB gastroesophageal reflux disease, which was released this month.

 

Fexuclu is expecting sales of 100 billion won.

 

Although it is not known to the media, it is analyzed that the pipeline of new drugs will also contribute to the rise in sales.

 

Daewoong Pharmaceutical signed four drug sales contracts with other companies last year, all of which are expected to have high sales in a short period of time.

 

Lundbeck signed a joint sales contract with Lexapro last December.

 

Lexapro is the number one item in the antidepressant market.

 

Based on last year's UBIST, it is a large product with an out-patient prescription of 22.2 billion won.

 

Daewoong signed a contract with Ebixa Corporation for dementia treatment in 2019 and is expanding cooperation with Lundbeck by jointly selling Lexapro.

 

It is also worth paying attention to the contract, an exclusive license in Korea, for Viatris and Herceptin biosimilar Ogivri in September last year.

 

Ogivri was approved by Alvogen Korea in August 2020.

 

However, since then, the license holder has been changed to Daewoong Pharmaceutical.

 

It is also being released with a salary in November 2020.

 

Ogivri is the third Herceptin biosimilar to compete with Celltrion Herzuma and Samsung Bioepis Sampenet.

 

Competition for the three items is expected to intensify as Daewoong Pharmaceutical holds domestic copyrights.

 

Alymsys, an Avastin biosimilar waiting to be reimbursed, is also a rising star.

 

Alymsys is an item authorized by Alvogen Korea earlier this year.

 

Prior to this, in October last year, Daewoong signed an exclusive distribution and sales contract with Alvogen for Alymsys in Korea.

 

As a result, when the salary is released, Daewoo will be in charge of domestic sales.

 

Currently, Avastin biosimilar has been released only in Korea by Samsung Bioepis.

 

Given that the original Avastin has a market worth 120 billion won in Korea, high sales are expected if it settles down well as a biosimilar.

 

The last contract signed last year was signed with LG Chem.

 

Currently, LG Chem has a joint sales contract with DPP-4 diabetes treatments Zemiglo and Zemimet, and in addition, a license contract was added in November last year to develop Gemigliptin and Enavogliflozin complex.

 

Enavogliflozin is an SGLT-2 diabetes drug developed by Daewoong.

 

It is analyzed that it is an attempt to increase its grip on the diabetes market by developing a complex that combines Zemiglo.